1. 1) National Comprehensive Cancer Network : NCCN Clinical Practice Guidelines in Oncology: Head and Neck Cancers. Ver. 1, 2020. https://www.nccn.org/professionals/physician_gls/default.aspx
2. 3) Ang KK : Concurrent radiation chemotherapy for locally advanced head and neck carcinoma: are we addressing burning subjects? J Clin Oncol 22: 4657–4659, 2004.
3. 4) Loong HH, Ma BB, Leung SF, et al. : Prognostic significance of the total dose of cisplatin administered during concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma. Radiother Oncol 104: 300–304, 2012.
4. 6) Nakano K, Sato Y, Toshiyasu T, et al. : Predictive factors of head and neck squamous cell carcinoma patient tolerance to high-dose cisplatin in concurrent chemoradiotherapy. Mol Clin Oncol 4: 303–309, 2016.
5. 7) Zenda S, Onozawa Y, Tahara M, et al. : Feasibility study of single agent Cisplatin and concurrent radiotherapy in Japanese patients with squamous cell carcinoma of the head and neck: preliminary results. Jpn J Clin Oncol 37: 725–729, 2007.